Earnings

ArriVent BioPharma To Present Initial Safety, Efficacy Results Of Its Phase 1 Trial Of CDH17-Targeted ADC ARR-217 In Participants With Gastrointestinal Cancers At ESMO Congress 2026

Oct 23, 2026 · 04:02 PM ET· updated 1h ago

ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that initial safety

Why It Matters

ArriVent will show early test results for a new cancer medicine. When companies share positive early data, it can mean the medicine is working the way they hoped.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

AVBP21.01

+1.81 (+9.43%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.